Business Context and Reporting Period
Company: Propanc Biopharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 2, 2020
Event: Entry into a Material Definitive Agreement involving the issuance of a convertible promissory note.
Key Financial Metrics
This filing reports a specific financing transaction rather than periodic financial performance. Key metrics related to the transaction include:
- Principal Amount: $78,000
- Net Proceeds: $75,000 (after fees and expenses)
- Transaction Fees: $3,000 paid to the investor
- Interest Rate: 8% per annum (payable in cash or shares)
- Maturity Date: December 2, 2021
- Use of Proceeds: General working capital
Note: The filing text does not provide clear values for the company's overall revenue, profit, cash flow, margins, or total debt levels outside of this specific note.
Material Changes and Transaction Terms
The Company entered into a Securities Purchase Agreement with Geneva Roth Remark Holdings, Inc. ("Geneva"). The transaction closed on or about December 4, 2020. Material terms include:
- Conversion Rights: Geneva may convert the note into common stock starting May 30, 2021. The conversion price is set at 65% of the "Market Price" (a 35% discount), based on the average of the lowest three trading prices over the ten trading days prior to conversion.
- Conversion Cap: Geneva is restricted from converting if the resulting ownership exceeds 4.99% of outstanding shares.
- Prepayment Penalties: The note may be prepaid within 180 days of issuance with escalating premiums ranging from 110% to 129% of the face amount plus accrued interest, depending on the timing of prepayment.
- Default Provisions: Upon an event of default, the outstanding principal and accrued interest increase to 150% (the "Default Amount").
Guidance, Risks, and Contingencies
Management Commentary: The Company intends to use the net proceeds for general working capital purposes. No specific forward-looking guidance regarding product development or revenue targets is provided in this filing.
Risks and Contingencies:
- Dilution Risk: The 35% discount on the conversion price and the potential for interest to be paid in shares may result in significant dilution to existing shareholders.
- Liquidity Risk: The Company is restricted from selling substantially all assets without Geneva's consent, which could limit strategic flexibility.
- Default Risk: Events of default include failure to maintain OTC listing, failure to file SEC reports, insolvency, or failure to reserve five times the number of shares issuable upon conversion.
- Penalty Risk: A $1,000 penalty applies if shares are not delivered within three business days of a conversion notice (unless caused by a third party).
Investor Verification Checklist
- Verify the current trading volume and price of PPCB on the OTC Pink market to assess the potential dilution impact of the 35% conversion discount.
- Confirm the Company's current cash position to determine if the $75,000 net proceeds are sufficient for stated working capital needs.
- Review the Company's recent SEC filings to ensure compliance with reporting requirements, as failure to do so constitutes an event of default under this note.
- Check the total number of authorized but unissued shares to ensure the Company can meet the covenant to reserve five times the shares issuable upon full conversion.
- Assess the financial stability of the investor, Geneva Roth Remark Holdings, Inc., given the significant control rights and default provisions granted.